Anti-Müllerian hormone (AMH) is a key biomarker for fertility assessment, but current diagnostic methods lack cost-effectiveness. Plasmonic biosensors can effectively detect low-concentration protein interactions. This study developed a sensitive, label-free surface plasmon resonance (SPR) sensor for AMH detection. Protein G was used to bind anti-AMH antibodies onto a gold chip coated with 11-MUA. Various AMH concentrations were measured to create a standardized graph, establishing limits of detection (LOD) and quantification (LOQ). The biosensor also tested patient serum samples for AMH detection, comparing the results with those obtained from enzyme-linked immunosorbent assay (ELISA) and localized surface plasmon resonance (LSPR) using silica@Au-NRs with anti-AMH antibodies. The detection results indicated a high sensitivity of the nanobiosensors, with LOD and LOQ for the gold chip at 0.6 ng/mL and 1.78 ng/mL, respectively, closely matching those of ELISA and silica@Au-NRs. Additionally, SPR-based biosensors reduce detection costs and measurement time, making them strong candidates for integration into diagnostic kits.
No takes yet. Share an insight, caveat, or question.
Mirshekari et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: